John Garner

Maleimide-PEG-PLGA from PolySciTech used in development of targeted nanoparticle brain-cancer therapy

Blog Post created by John Garner on Mar 22, 2018

Hua, 2018 glioma nanoparticle cancer docetaxel.jpg

Brain cancer is doubly difficult to treat as most chemotherapeutics are cytotoxic and uptake to the tumor is poor due to the blood-brain-barrier. Recently, researchers at Yantai University (China) used PLGA-PEG-Mal (Polyvivo AI020) from PolySciTech (www.polyscitech.com) to generate targeted nanoparticles for treating glioma. This research holds promise for improved therapy of brain cancer. Read more: Hua, Hongchen, Xuemei Zhang, Hongjie Mu, Qingqing Meng, Ying Jiang, Yiyun Wang, Xiaoyan Lu et al. "RVG29-modified Docetaxel-loaded nanoparticles for brain-targeted glioma therapy." International Journal of Pharmaceutics (2018). https://www.sciencedirect.com/science/article/pii/S0378517318301753

“Abstract: Gliomas are the most common malignant brain tumor, but treatment is limited by the blood–brain barrier (BBB), especially for chemotherapeutic drugs. Although some chemotherapy drugs can pass through the BBB, many of these agents are toxic to normal brain tissue. To maximize therapeutic effects, chemotherapeutic drugs must accumulate at the glioma site. In this study, a specific ligand (the RVG29 peptide) that can combine with acetylcholine receptors was conjugated to polyethylene glycol-modified poly-(D,L-lactide-co-glycolide) (PEG-PLGA) to develop a targeted carrier; preparation of the targeted docetaxel nanoparticles (DTX-NPs) was performed by the nanoprecipitation method. The NPs were approximately 110 nm and had smooth surfaces. Enzyme-linked immunoassay results showed that the amount of receptor on the surface of glioma cells was 2.04-fold higher than that of nonmalignant cells, which may promote accumulation of RVG29-modified NPs at the targeting site. NPs showed targeting properties for glioma cells compared with the non-targeting NPs in an in vitro cellular uptake test. Targeted NPs also showed better BBB penetration in an in vitro model. In vivo tests indicated that RVG29-PEG-PLGA-NPs could selectively accumulate in intracranial glioma tissue. In conclusion, these results indicated that the RVG29-modified NPs have potential efficacy for glioma therapy. Keywords: Brain-targeting; glioma; RVG29; blood–brain barrier; Docetaxel”

-

  BPCR conference

(August 29, 2018 9AM - 4PM: Kurz Purdue Technology Center, West Lafayette, IN) is a free, 1-day scientific networking conference hosted by Akina, Inc. which focuses on research companies in the biotechnology, pharmaceutical, medical, and broader life-science fields. See more at BPCRconference.com

Outcomes